Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

Br J Haematol. 1998 Sep;102(5):1115-23. doi: 10.1046/j.1365-2141.1998.00930.x.

Authors

J Bladé¹, D Samson, D Reece, J Apperley, B Björkstrand, G Gahrton, M Gertz, S Giralt, S Jagannath, D Vesole

Affiliation

¹ Department of Haematology, Hospital Clinic, IDIBAPS, Barcelona, Spain.

PMID: 9753033
DOI: 10.1046/j.1365-2141.1998.00930.x

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / administration & dosage*
Disease Progression
Hematopoietic Stem Cell Transplantation / methods*
Humans
Multiple Myeloma / therapy*
Recurrence
Treatment Outcome

Substances

Antineoplastic Agents